Clinical Evaluation Evidence: Class III/IV Devices and Local Clinical Data

1. Key takeaways

The EDE marketing authorization service page requires safety and effectiveness data for Class III and Class IV products, which echoes Article 6(1)(c) of Federal Decree-Law No. 38/2024: item (c) requires an assessment of the compliance of the reference-country marketing authorization together with an assessment of the clinical evaluation and post-market outcomes. Our judgment is that the UAE has not made local clinical trials a default threshold. The evidence main line for high-risk products is clinical evidence already reviewed in a reference country plus post-market outcomes; local data become a necessary supplement only when the existing evidence cannot be extrapolated.

• The EDE service page requires safety and effectiveness data for Class III and IV products, submitted alongside EC, 510(k) or PMA documents according to the classification, with a service turnaround of 45 working days.
• Article 6(1)(c) asks for an organised clinical evaluation and post-market outcomes, not a stack of raw reports.
• Local clinical data are triggered by a failure of extrapolation, not by the device class alone; Class III and IV status does not automatically require a UAE local trial.
• Article 19 on the handling of academic misconduct makes the traceability of clinical data sources, signatures and versions a long-term obligation.

2. Legal basis

The clinical evidence requirements for high-risk devices rest on Article 6 of Federal Decree-Law No. 38/2024, on the data requirements of the EDE service page, and on Article 19, summarised below.

3. Expert insights

Insight 1: Reliance on existing evidence has preconditions; it is not accepted unconditionally. Article 6(1)(c) requires an assessment of the clinical evaluation and post-market outcomes, which means what EDE wants to see is an organised clinical evaluation rather than a heap of raw reports. Our practice is to link the clinical evaluation report already reviewed in a reference country, the post-market follow-up results and the adverse event trends into one chain of argument, and to state expressly the extrapolability of the data across populations, use environments and operator habits. Without that layer of argument, material of the same thickness can receive different review conclusions.

Insight 2: The trigger for local data is a failure of extrapolation, not a high class on its own. Class III and IV products are not automatically required to run local clinical trials in the UAE; supplementary local data become necessary only when the existing evidence differs materially from the target population, the clinical practice or the environmental conditions. We apply three criteria: whether the characteristics of the target population differ, whether the operators are professional healthcare personnel, and whether the post-market data sufficiently cover the known risks. Only when any one of the three fails do we start a local data programme.

Insight 3: In the gap period, the depth of evidence should be asked for, not guessed. The Executive Regulations under the Decree-Law have not yet all been issued, Article 6(1)(h) reserves further conditions, and the reference authority list is being updated. On high-risk projects we insist on first obtaining the written view of EDE on the scope of the evidence, before deciding whether to add clinical data or supplement post-market studies. At the same time we flag Article 19 on the handling of academic misconduct: the sources, signatures and version records of clinical data must be traceable, and this is something that cannot be fixed by supplementary paperwork after the fact.

4. Practical recommendations

• Take the clinical evaluation report already reviewed in a reference country as the main line, paired with post-market outcomes, forming a complete chain of argument.
• Provide a written account of extrapolability, comparing population characteristics, operator type, use environment and known risk trends item by item.
• Start a local clinical data programme only when one of the three criteria fails, and confirm the scope with EDE before the filing.
• Build version and provenance records for clinical data, with signing entities, dates and report numbers traceable, answering the compliance requirement of Article 19.
• Plan post-market follow-up and PMCF arrangements for high-risk products in parallel, linking them to the system requirements of Article 6(1)(b).
• Where the scope of evidence is in doubt, obtain written confirmation from EDE first, before committing the cost of local studies.

5. Verification checklist

• □ The safety and effectiveness data for Class III and IV products have been prepared as required by the EDE service page.
• □ The clinical evaluation report comes from a version already reviewed in a reference country, and its version and date are traceable.
• □ A written argument on the extrapolability of populations, operators and use environments has been made.
• □ The grounds for starting a local data programme are recorded, and a written view from EDE on the evidence scope has been obtained.
• □ The sources, signing entities and version records of the clinical data are complete and can answer the requirements of Article 19.
• □ Post-market follow-up and PMCF arrangements are in the plan, with interfaces consistent with the vigilance system.

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the United Arab Emirates. Our team manages MOHAP registration applications, prepares reference-approval dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com